| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Biochemistry and
Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Both TCR and BCR signaling have been linked with the engagement of similar sets of intracellular signal transducers including protein tyrosine kinases, tyrosine phosphorylated adaptors, and phospholipase C (PLC)3 (6). The latter enzyme cleaves membrane phosphatidylinositol to generate diacylglycerol (DAG) and calcium messengers. Traditionally, the effects of DAG signaling have been attributed to the activation of the protein kinase C (PKC) family members (7).
Another protein implicated in immune receptor signaling is Ras, a small membrane-bound GTPase. Conversion of Ras-GDP to Ras-GTP leads to stimulation of various downstream pathways such as the Raf-Mek-Erk kinase cascade, with ensuing changes in transcription and other cellular responses. Early studies suggested that Ras in lymphocytes was regulated by PKC-mediated down-regulation of Ras GTPase activating proteins (8), or by membrane recruitment of Sos (9, 10, 11), a Ras guanyl nucleotide exchange factor (Ras GEF). We proposed that upon TCR engagement, PLC
-1 activation and DAG accumulation led to activation of RasGRP1, a Ras GEF (12, 13). RasGRP activation is controlled both by membrane recruitment through its DAG binding C1 domain (14, 15, 16, 17) and by DAG responsive kinases (18, 19, 20, 21).
Strongly supporting this model, thymocytes from Rasgrp1–/– mice are defective in TCR- and DAG-induced activation of Ras-Erk signaling (13). Furthermore, young mutant mice exhibit a defect in positive selection as evidenced by a deficiency of single-positive thymocytes and peripheral T cells (13, 22). Notably, however, aged mice that lack RasGRP1 develop a paradoxical autoimmune disorder typified by serum autoantibodies, including antinuclear Abs reminiscent of those seen in systemic lupus erythematosus (23). Hallmarks of this murine syndrome are pronounced splenomegaly and lymphoproliferation, bearing in mind that this latter term is used to denote an abnormal increase in lymphocyte populations that occurs by a combination of increased multiplication and/or decreased cell death. The relatively rare thymocytes that do develop into T cells in the absence of RasGRP1 are activated and self-reactive. These T cells were proposed to lead secondarily to the B cell dysfunction in aged Rasgrp1–/– mice.
B cells express both RasGRP1 and RasGRP3 (18, 19, 20, 24, 25). Experiments with chicken DT40 cells have shown that RasGRP3 plays a key role in linking BCR to Ras, whereas RasGRP1 and Sos proteins play insignificant roles in this process (25). To study RasGRP3 function in the context of the mammalian immune system, we generated Rasgrp3–/– mice and studied their B cell phenotypes. Rasgrp1–/– and Rasgrp1–/–Rasgrp3–/– mice were also studied.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Rasgrp3 mutant mice were derived on a 129/J and C57BL/6J (B6) hybrid background essentially as previously described for Rasgrp1 mutant mice (13). Briefly, a neo cassette was inserted into the BstX1 site in the second exon of Rasgrp3 in NX1 ES cells, interrupting the coding sequence downstream of codon 40 in the Ras exchange motif (REM box) of the catalytic region. Rasgrp3 null mice were viable, fertile, and lacked any overt phenotype. We previously reported that homozygous Rasgrp1 null mice displayed reduced viability in this background (13), but such an effect has not been evident in subsequent work. In crosses between Rasgrp1–/– and Rasgrp3–/– mice on a mixed background, single and double homozygous mice were observed in approximately expected Mendelian ratios. Age- and sex-matched siblings from multiple matings were compared to randomize the effect of genetic background and minimize the effect of environment. The genotypes of all homozygous null mutant mice were determined by PCR. Genotyping results were verified by immunoblotting protein extracts with RasGRP1 and RasGRP3 Abs. Mice were bred under viral Ab-free conditions. All animal studies were done according to protocols approved by The Health Sciences Animal Policy and Welfare Committee at the University of Alberta, in accordance with Canadian Council on Animal Care Guidelines.
Reagents and Abs
PMA was purchased from Sigma-Aldrich. LPS was purchased from Sigma-Aldrich. Goat anti-mouse anti-IgM was from Southern Biotechnology Associates, hamster anti-mouse CD40 (HM40-3) was from BD Biosciences, recombinant mouse IL-4 was from BioSource International, anti-phosphotyrosine (4G10) and pan-Ras Ab (RAS10) were from Upstate Biotechnology, and the phospho-Erk Ab (9101) was from Cell Signaling Technology. Abs directed against RasGRP1 and RasGRP3 have been previously described (20, 26). CFSE (no. C1157) was from Molecular Probes. The reagents 2,4,6-trinitrophenyl (TNP)-BSA, TNP-LPS, and TNP-keyhole limpet hemocyanin (KLH) were purchased from Biosearch Technologies.
Cell enrichment and immunofluorescence
B cells and T cells were enriched by negative selection of undesired splenocytes, using B cell or pan T cell isolation kits, respectively, as per manufacturer’s instructions (Miltenyi Biotec). This resulted in cell purities of 90–98% as determined by flow cytometry. B cell isolation kits remove cells expressing CD43 (several non-B cell types, activated B cells, plasma B cells, B1 cells), CD4 (T cell subset), and Ter119 (erythrocytes). B cells isolated by this method were either IgM+ or IgMlow, and all were lacking CD69 plus CD138 expression (data not shown). Antinuclear Abs were detected on HEp-2 slides (Bio-Rad) using serum samples from 3- to 6-mo-old mice at a 1/50 dilution.
Signaling assays
For signaling experiments, splenic B cells from 5- to 6-wk-old mice were incubated at 37°C for 30 min in serum-free RPMI 1640 after enrichment at 0–4°C. Equal numbers of cells were then treated for indicated times with either 100 nM PMA or 20 µg/ml anti-IgM. Cells were then recovered by centrifugation and lysed as described previously (20). The Ras activation assay has been described previously (20). Lysates were run on SDS-PAGE, transferred to a filter and probed with the indicated Abs.
Flow cytometry
Single-cell suspensions of splenocytes were stained with fluorescent-labeled Abs (BD Biosciences) and analyzed by flow cytometry using a BD Biosciences FACSCalibur or FACSCanto to acquire the data and then analyzed using Flowjo software (Tree Star).
Immunizations and ELISA
To determine immune responses, mice were immunized by i.p. injection with 100 µg of TNP-KLH (T cell-dependent) or 20 µg of TNP-LPS (T cell-independent type I) in 100 µl of PBS on days 0 and 14. Mice were bled before the first immunization (day 0) as well as on days 7, 14 (before secondary immunization), 21, and 28. For aged basal serum Ab titers, 3- to 6-mo-old mice were bled. IgM, IgA, IgG1, IgG2a, IgG2b, and IgG3 were quantified using SBA Clonotyping System/HRP (Southern Biotechnology Associates) according to the manufacturer’s instructions. IgE was quantified using BD OptEIA mouse IgE ELISA set according to the manufacturer’s instructions. For total Ab levels, plates were coated with goat anti-mouse Ig capture Ab, whereas for TNP-specific Ab levels, plates were coated with 10 µg/ml TNP-BSA. Values were obtained by serially diluting samples and using dilutions that fell within a standard curve using isotype-specific controls (Southern Biotechnology Associates).
Proliferation assays
For CFSE-labeling, B cells, or CD4+ T cells from the spleens of 6-wk-old mice, were labeled according to the originally published method (27). B cells were cultured at 105 cells in 1 ml of medium with various combinations of the following: 20 µg/ml anti-IgM, 10 ng/ml IL-4, 10 µg/ml anti-CD40, and 20 µg/ml LPS. Following 4 day treatments, cells were analyzed by flow cytometry. For all CFSE-labeling experiments, equal numbers of cells were analyzed, although flow cytometry histograms are shown with variable axes because of the reduced viability of double-knockout B cells. Average number of cell divisions and the percentage of divided cells were calculated by analyzing flow cytometry results using the Flowjo proliferation platform.
BrdU labeling was used to detect S phase cells. Splenic B cells were allowed to proliferate in medium alone or in combination with the indicated stimulus. After 3 days incubation, cells were exposed for 1 h to BrdU in culture medium. Cells were then fixed, permeabilized, and stained with anti-BrdU and 7-aminoactinomycin D following the manufacturer’s instructions (BD Biosciences). Cells were then analyzed by flow cytometry.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
We first performed immunoblotting to determine whether both RasGRP1 and RasGRP3 are expressed in splenic B cells, as they are in several B cell lines (20, 24, 25). As expected, wild-type B cells express both RasGRP1 and RasGRP3 (Fig. 1A). In contrast, splenic T cells express only RasGRP1. These species are missing in extracts from the corresponding null mutant mice. Furthermore, the expression level of one RasGRP species is not affected by the status of the other. Notably, T cells express substantially more RasGRP1 then do B cells. RasGRP2 is a Rap activator whereas RasGRP4 expression has been documented only in mast and myeloid tumor cells (28, 29, 30, 31), so these family members were not studied.
|
In parallel cultures, treatment with soluble anti-IgM Abs was used to simulate Ag-BCR ligation. Compared with PMA-treated cells, activation of Ras and Erk was weaker (Fig. 1B). Relative to wild-type cells, Rasgrp1–/– B cells showed slightly weaker Ras and Erk activation. Interestingly, Rasgrp3–/– B cells exhibited undetectable basal Ras-GTP levels as well as defective BCR-induced Ras activation. At later time points, the activation of Erk was intermediate in each mutant compared with wild-type cells and totally absent in the double-mutant cells. Taken together these results indicate that, although each RasGRP species studied has a distinct role in regulating Ras in splenic B cells, there is also some functional redundancy.
We examined the level of total cell protein tyrosine phosphorylation as a proxy for early BCR signaling events. Numerous phosphorylated proteins were observed after BCR stimulation but these were not significantly affected by genotype (Fig. 1C). These results indicate that early BCR signaling events are not influenced by RasGRP activity. They support the argument that the defects in Ras and Erk activation as we previously referred to are specific, direct effects of reduced Ras GEF activity. Furthermore, from the equivalent phosphotyrosine responses, one might argue that these cell populations derived from the four different genotypes are functionally comparable in terms of early BCR signaling events.
RasGRP3 deficiency decreases humoral function and suppresses Rasgrp1–/– autoimmunity
To determine the biological consequences of decreased Ras activation due to RasGRP1 and RasGRP3 loss, we examined several immunological parameters in mice of various genotypes and ages. As reported previously (23), Rasgrp1–/– mice develop splenomegaly at 2–3 mo of age (Fig. 2A). This phenotype apparently arises from a defect in T cell development, which leads to lymphoproliferation and autoimmunity. Splenomegaly was never seen with Rasgrp3–/– mice. Surprisingly, splenomegaly was also never observed in aged double-mutant mice. The suppression of the Rasgrp1–/– lymphoproliferative phenotype by the Rasgrp3 null mutant was also apparent from the numbers of cells recovered per spleen (Fig. 2B).
|
B cell development does not require RasGRP1 or RasGRP3
We used surface marker analysis to determine whether a lack of BCR-induced Ras activation in double-mutant mice caused a defect in B cell development. Previously, Nagaoka et al. (32) demonstrated that expression of an inhibitory form of Ras during early B cell development negatively influenced cell survival. In the spleen, immature B cells (T1) pass through an intermediate stage (T2) before becoming mature cells (M). We found that peripheral B cell development occurs largely normally in the absence of RasGRP1 and/or RasGRP3, both in terms of total B cells per spleen and the relative ratios of B cells in T1, T2, and M stages (Fig. 3, A and B), with the variability between genotypes being less than that found within a given genotype. One consistent variation was an increase in the proportion of otherwise rare CD138+ cells in Rasgrp1–/– mice, indicating an expanded population of plasma cells (Fig. 3C). Double-mutant mice always had relatively lower levels of these cells, further confirming that Rasgrp3–/– can act to suppress the syndrome associated with aged Rasgrp1–/– mice. The increased CD138+ population was generally observed in 6-wk-old Rasgrp1–/– mice and therefore presages the development of the late-onset autoimmunity.
|
RasGRP deficiencies affect humoral responses to specific immunogens
We used the hapten-carrier system to determine the consequences of defective BCR-Ras signaling on Ab responses following immunization of our mutant mice. T cell-dependent Ags require T cell help to generate an effective B cell response. The immunogen is a hapten conjugated to a protein. T cell-independent type I Ags contain a polyclonal activator of B cells such as LPS conjugated to a hapten (33).
Compared with wild-type mice, Rasgrp1–/– mice were able to generate similar levels of hapten-specific Abs in the T cell-dependent protocol (Fig. 4). Depending on the Ig isotype, Rasgrp1–/– mice produced equal or even greater titers in the T cell-independent responses. In particular, IgG1 and IgG2a levels were higher in the Rasgrp1–/– mutant, possibly reflecting a constitutive T cell influence that is not normally elicited by this injection protocol.
|
RasGRPs are required for BCR-induced proliferation in vitro
Proliferation of B cells is required for Ig class switching and differentiation into mature Ab secreting plasma cells (34). Furthermore, T cells that lack RasGRP1 exhibit reduced proliferative responses (22, 23). Accordingly, we examined the roles of RasGRP1 and RasGRP3 in B cell proliferation induced by various stimuli. B cells prepared from young mice were labeled with CFSE and then cultured with or without stimulation for 4 days. Flow cytometry was used to monitor dilution of cellular label, providing a measure of both the percentage of cells that had divided and the average number of cell divisions.
Treatment with either anti-IgM Abs or IL-4 alone was ineffective at inducing proliferation, whereas costimulation with both agents induced substantial proliferation of wild-type B cells (Fig. 5A). This response was largely intact in RasGRP1 single-mutant B cells, more dramatically affected by the loss of RasGRP3, and totally absent in the double-mutant cells. The results directly parallel those of our biochemical analysis of BCR-Ras-Erk signaling.
|
The CFSE-labeling experiments revealed the net effect of proliferative stimulation over 4 days. To verify these findings with an independent method, cells were incubated for 1 h with BrdU to label the fraction of cells actively engaged in DNA replication at the end of the culturing period, followed by anti-BrdU Ab staining and flow cytometry analysis. Compared with wild-type cells, Rasgrp1 and Rasgrp3 single-mutant B cells retained some ability to respond to anti-IgM plus IL-4, but double-mutant B cells were virtually inactive in this assay (Fig. 5B). Overall, both sets of data support the hypothesis that RasGRP3 plays a more important role than RasGRP1 in BCR-induced proliferation, with partial redundancy evident in most circumstances.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Oh-hora et al. (25) generated RasGRP1 and RasGRP3 single and double deficient DT40 chicken B cells. In these cells, BCR-Ras signaling depends on RasGRP3 but not RasGRP1. These transformed chicken B cells did not display detectable tonic BCR-Ras signaling and, in the absence of both RasGRPs, there was residual Ras-Erk signaling upon BCR ligation. Thus, the mechanism of BCR-Ras signaling in DT40 cells is different from that of murine splenic B cells.
A major finding of our study is the dependence of in vitro BCR-induced proliferation on RasGRP1 and RasGRP3. In our assays, RasGRP3 plays a more important role than RasGRP1 although both RasGRPs are roughly equivalent in anti-IgM plus IL-4 costimulation assays. In vivo, B cell proliferation is important for controlling activation, differentiation, and class-switching (34). Therefore, we expected double-mutant mice to exhibit substantial disruption of the B cell compartment. Surprisingly, B cell development appears to proceed normally in the absence of both RasGRP1 and RasGRP3 as judged by surface marker analysis of splenocytes. Mice deficient in PLC-2 have only a mild B cell developmental defect, which likely reflects a failure to activate RasGRPs as well as other molecules such as PKC (37, 38). These results are in contrast to the severe B cell developmental defects seen in mice expressing a dominant-negative Ras mutant under the control of a B cell-specific promoter (32, 39). However, the developmental defect in RasN17 transgenic mice occurs before the expression of the pre-BCR and is likely due to inhibition of IL-7R signaling. Possibly other GEFs, such as Sos, are the targets of the dominant-negative Ras in early stages of development.
We have established that RasGRP1 and RasGRP3 play important roles in Ig production by examining sera from both aged and young mice immunized by standard protocols. Compared with wild-type mice, aged Rasgrp1–/– mice have elevated serum Ig levels, whereas Rasgrp3–/– mice have reduced levels. Curiously, Ig levels in double-mutant mice are intermediate between those seen in either single mutant. In Rasgrp1–/– mice the elevated Ig levels are likely a result of an indirect effect of autoimmune T cells, whereas the hypogammaglobulinemia in Rasgrp3–/– mice probably arises from reduced BCR-Ras signaling. The intermediate values observed in double-mutant mice could reflect a balance of these two effects. Young Rasgrp3–/– and double-mutant mice also have minor defects in the production of hapten-specific Abs.
Our analysis of serum Ig levels revealed some puzzling isotype-specific effects of RasGRP deficiency. Previous studies showed that CD4+ T cells from autoimmune Rasgrp1–/– mice produce high amounts of IL-4 upon in vitro stimulation (23). This cytokine induces IgG1 and IgE synthesis (40), consistent with the elevated titer of these Ig isotypes that we observed in aged Rasgrp1–/– mice. However, Rasgrp1–/– T cells produced negligible IFN- in vitro, so it is unclear why these mice have elevated titers of IgG2a and IgG3. Additional cytokine abnormalities, possibly arising from non-T cells, may be influencing B cells in Rasgrp1–/– mice. In addition, the isotype-specific differences that we observed in both our immunized and nonimmunized double-mutant mice are unexplained, because they do not match the deficiencies reported for other mouse mutants with B cell proliferation defects. For example, PLC-2-deficient mice lack BCR-induced proliferation but exhibit decreased levels of IgM, IgG2a, and IgG3 in their sera and have normal T cell-dependent immune responses (37, 38). Likewise, loss of cyclin D2, a likely effector of BCR-Erk signaling, results in decreased serum levels of IgG3 and IgA (41).
Mice that lack RasGRP1 expression in their T cells develop a late onset lymphoproliferative and autoimmune syndrome (23). Although this process complicates the analysis of RasGRP1 and RasGRP3 function in B cells from aged mice, our studies revealed that the Rasgrp1–/– autoimmunity is suppressed in double-mutant mice. The loss of RasGRP1 expression in T cells has been shown to result in excess IL-4 production upon TCR stimulation in vitro (23). Although IL-4 plus anti-IgM induces proliferation of wild-type and Rasgrp1–/– B cells, double-knockout B cells are not responsive to this treatment. We hypothesize that the lack of autoimmunity and splenomegaly in Rasgrp1-Rasgrp3 double-mutant mice is due to the proliferation defect of B cells, which causes them to be less responsive to the signals originating from autoimmune T cells.
|
Acknowledgments |
|---|
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 This work was supported by grants from the Canadian Institutes of Health Research and the Alberta Heritage Foundation for Medical Research. 
2 Address correspondence and reprint requests to Dr. James C. Stone, Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada. E-mail address: jim.stone{at}ualberta.ca
3 Abbreviations used in this paper: PLC, phospholipase C; DAG, diacylglycerol; PKC, protein kinase C; GEF, guanyl nucleotide exchange; KLH, keyhole limpet hemocyanin; TNP, 2,4,6, trinitrophenyl.
Received for publication July 14, 2005. Accepted for publication September 23, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
1, and other phosphoproteins with Grb2 and the 
-chain of the TCR. J. Biol. Chem. 270: 18428-18436. chain of the T cell receptor upon T cell activation. Science 262: 902-905. 2 to Ras in B cell receptor signaling. J. Exp. Med. 198: 1841-1851. 
activates RAF-1 by direct phosphorylation. Nature 364: 249-252. [Medline]
2 is essential in the functions of B cell and several Fc receptors. Immunity 13: 25-35. [Medline]
2 regulates Bcl-2 levels and is required for survival rather than differentiation of marginal zone and follicular B cells. Eur. J. Immunol. 34: 2237-2247. [Medline]
This article has been cited by other articles:
|
|
 |
|
  Y. Imamura, A. Oda, T. Katahira, K. Bundo, K. A. Pike, M. J. H. Ratcliffe, and D. Kitamura BLNK Binds Active H-Ras to Promote B Cell Receptor-mediated Capping and ERK Activation J. Biol. Chem., April 10, 2009; 284(15): 9804 - 9813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Frank, D. W. Dawson, S. J. Bensinger, J. S. Hong, W. M. Knosp, L. Xu, C. E. Balatoni, E. L. Allen, R. R. Shen, D. Bar-Sagi, et al. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas Blood, March 12, 2009; 113(11): 2478 - 2487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Weber, B. Treanor, D. Depoil, H. Shinohara, N. E. Harwood, M. Hikida, T. Kurosaki, and F. D. Batista Phospholipase C-{gamma}2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen J. Exp. Med., April 14, 2008; 205(4): 853 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pridans, M. L. Holmes, M. Polli, J. M. Wettenhall, A. Dakic, L. M. Corcoran, G. K. Smyth, and S. L. Nutt Identification of Pax5 Target Genes in Early B Cell Differentiation J. Immunol., February 1, 2008; 180(3): 1719 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Katsoulotos, M. Qi, J. C. Qi, K. Tanaka, W. E. Hughes, T. J. Molloy, R. Adachi, R. L. Stevens, and S. A. Krilis The Diacylglycerol-dependent Translocation of Ras Guanine Nucleotide-releasing Protein 4 inside a Human Mast Cell Line Results in Substantial Phenotypic Changes, Including Expression of Interleukin 13 Receptor {alpha}2 J. Biol. Chem., January 18, 2008; 283(3): 1610 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ikuta, H. Edamatsu, M. Li, L. Hu, and T. Kataoka Crucial Role of Phospholipase C{varepsilon} in Skin Inflammation Induced by Tumor-Promoting Phorbol Ester Cancer Res., January 1, 2008; 68(1): 64 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ko, L. M. Joshi, L. L. Cooke, N. Vazquez, M. W. Musch, S. C. Hebert, G. Gamba, and R. S. Hoover Phorbol ester stimulation of RasGRP1 regulates the sodium-chloride cotransporter by a PKC-independent pathway PNAS, December 11, 2007; 104(50): 20120 - 20125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Luke, C. E. Oki-Idouchi, J. M. Cline, and P. S. Lorenzo RasGRP1 Overexpression in the Epidermis of Transgenic Mice Contributes to Tumor Progression during Multistage Skin Carcinogenesis Cancer Res., November 1, 2007; 67(21): 10190 - 10197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yasuda, R. L. Stevens, T. Terada, M. Takeda, T. Hashimoto, J. Fukae, T. Horita, H. Kataoka, T. Atsumi, and T. Koike Defective Expression of Ras Guanyl Nucleotide-Releasing Protein 1 in a Subset of Patients with Systemic Lupus Erythematosus J. Immunol., October 1, 2007; 179(7): 4890 - 4900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Beaulieu, B. Zahedi, R. E. Goulding, G. Tazmini, K. V. Anthony, S. L. Omeis, D. R. de Jong, and R. J. Kay Regulation of RasGRP1 by B Cell Antigen Receptor Requires Cooperativity between Three Domains Controlling Translocation to the Plasma Membrane Mol. Biol. Cell, August 1, 2007; 18(8): 3156 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Roose, M. Mollenauer, M. Ho, T. Kurosaki, and A. Weiss Unusual Interplay of Two Types of Ras Activators, RasGRP and SOS, Establishes Sensitive and Robust Ras Activation in Lymphocytes Mol. Cell. Biol., April 1, 2007; 27(7): 2732 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. J. de Gorter, J. C. M. Vos, S. T. Pals, and M. Spaargaren The B Cell Antigen Receptor Controls AP-1 and NFAT Activity through Ras-Mediated Activation of Ral J. Immunol., February 1, 2007; 178(3): 1405 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rui, J. I. Healy, J. Blasioli, and C. C. Goodnow ERK Signaling Is a Molecular Switch Integrating Opposing Inputs from B Cell Receptor and T Cell Cytokines to Control TLR4-Driven Plasma Cell Differentiation J. Immunol., October 15, 2006; 177(8): 5337 - 5346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Irish, D. K. Czerwinski, G. P. Nolan, and R. Levy Kinetics of B Cell Receptor Signaling in Human B Cell Subsets Mapped by Phosphospecific Flow Cytometry J. Immunol., August 1, 2006; 177(3): 1581 - 1589. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
